Dr. Marks, Distinguished Professor in Radiation Oncology at the University of North Carolina at Chapel Hill, received a B.S. in Chemical Engineering (Cooper Union 1981), an M.D. (University of Rochester, 1985), had residency training at Massachusetts General Hospital, and was faculty at Duke for 19 years and joined UNC in 2008 as Chair of Radiation Oncology.
Clinically he focuses on breast and lung cancer. His research aims to improve the therapeutic ratio of radiation, largely through better understanding radiation-induced normal tissue injury. In particular, he has extensively studied radiation-induced damage in the lung and heart. He helped to lead an international effort to develop dose/volume/outcome standards called QUANTEC.
Dr. Marks is interested in human-factors engineering, has studied the frequency/causes of “human-errors” in the clinic, and has implemented systems aimed to reduce errors. He serves on several national committees aimed to improve patient safety. He has written many papers and recently a book about this sensitive issue.
Industry Expertise (3)
Health and Wellness
Areas of Expertise (7)
Radiation-Induced Normal Tissue Reactions
Radiation-Induced Injury to the Lung and Heart
Three-Dimensional Radiation Treatment
Massachusetts General Hospital: Residency, Radiation Medicine 1989
University of Rochester: M.D., Medicine 1985
Media Appearances (2)
Physicians experience increased effort, uncertainty in cross-coverage of radiation oncology patients
RxPG News online
In a paper presented at the 2013 American Society for Radiation Oncology conference, study authors Prithima Mosaly, PhD, and Lukasz Mazur, PhD, assistant professors in the UNC Department of Radiation Oncology; Bhishamjit Chera, MD, assistant professor of radiation oncology and Lawrence Marks, MD, Sidney K. Simon Distinguished Professor of Oncology Research and Chair, found a significant decrease in performance and confidence when physicians were asked to plan the treatment of an unfamiliar patient...
New QUANTEC guidelines for safe treatment of cancer with radiation therapy
News Medical online
"The new standards have resulted from a systematic review of radiation therapy dose/volume/outcome data on 16 organs. The new data was made possible by the more general use of 3D imaging during radiation planning. These new standards provide a logical framework to assess the risks of complex 3D doses that we now routinely consider," said Lawrence B. Marks, M.D., chair of the department of radiation oncology and co-editor of the QUANTEC study...
2010 ABSTRACT: The Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) review summarizes the currently available three-dimensional dose/volume/outcome data to update and refine the normal tissue dose/volume tolerance guidelines provided by the classic Emami et al. paper published in 1991. A “clinician's view” on using the QUANTEC information in a responsible manner is presented along with a description of the most commonly used normal tissue complication probability (NTCP) models. A summary of organ-specific dose/volume/outcome data, based on the QUANTEC reviews, is included...
2009 PURPOSE: To present guidance for patients and physicians regarding the use of accelerated partial-breast irradiation (APBI), based on current published evidence complemented by expert opinion...
2001 PURPOSE: To relate lung dose-volume histogram-based factors to symptomatic radiation pneumonitis (RP) in patients with lung cancer undergoing 3-dimensional (3D) radiotherapy planning. METHODS AND MATERIALS: Between 1991 and 1999, 318 patients with lung cancer ...
1998 PURPOSE: To determine the relation between the incidence of radiation pneumonitis and the three-dimensional dose distribution in the lung. METHODS AND MATERIALS: In five institutions, the incidence of radiation pneumonitis was evaluated in 540 patients. The patients were ...
1993 PURPOSE: We studied high-dose cyclophosphamide, cisplatin, and carmustine (CPA/cDDP/BCNU) with autologous bone marrow support (ABMS) as consolidation after standard-dose adjuvant chemotherapy treatment of primary breast cancer involving 10 or ...